Blocking of the SPAK–NKCC1 pathway with the novel SPAK inhibitor ZT-1a or NKCC1 inhibitor bumetanide protected ChP against the stroke-induced damage and oxidative stress-induced apoptosis. Here, STK39 is linked to Stroke.